Investors
Abalos Therapeutics is supported by a syndicate of prestigious life science investors including Boehringer Ingelheim Venture Funds, High-Tech Gründerfonds, NRW.Bank and Gründerfonds Ruhr.
Partners
We have established successful relationships with renowned academic and service partners and are always looking out for new collaborations to further advance our innovative immuno-virotherapy approach.
Governmental Support
Abalos and its scientific founders have been chosen in a highly competitive selection process as part of the KMU-innovativ to receive funding of €1.2M for 2 years for the advancement of arenavirus-based cancer therapies. The KMU-innovativ is an important initiative from the German Federal Ministry of Education and Research (German: “BMBF”) to support small and medium-sized enterprises (SMEs, German: “KMUs”) that are pioneering new technologies with a focus on cutting-edge R&D in several scientific and technical disciplines, including biomedicine. Recipients are chosen based on their scientific excellence, the project’s degree of innovation, the potential for an effective technology transfer and an application-oriented approach to developing novel therapeutics in areas of high medical need.
Supported by
